Related Experiment Video
Updated: Apr 15, 2026
Preparation of Small RNA Libraries for Sequencing from Early Mouse Embryos
Published on: October 9, 2020
MicroRNA biomarkers for early detection of embryonic malformations in pregnancy
1Department of Pharmacy, Affiliated Hospital of Yanbian University, Yanji, Jilin, China.
Insights
Early detection of birth defects is crucial for intervention. Cell-free microRNAs (miRNAs) in maternal blood show promise as sensitive biomarkers for embryonic developmental abnormalities.
Area of Science:
- Developmental Biology
- Biomarker Discovery
- Genetics
Background:
- Congenital birth defects arise during early embryogenesis, necessitating early detection for effective intervention.
- Current diagnostic methods like ultrasonography detect anomalies post-formation, while protein biomarkers lack sufficient sensitivity for early embryonic issues.
- Cell-free microRNAs (miRNAs) in maternal blood are emerging as potential disease biomarkers.
Purpose of the Study:
- To explore the potential of cell-free microRNAs (miRNAs) as sensitive and specific biomarkers for early detection of embryonic dysmorphogenesis and congenital birth defects.
Main Methods:
- Analysis of cell-free microRNAs (miRNAs) expression in maternal plasma.
- Correlation of miRNA expression patterns with fetal anomalies and infant birth defects.
- Evaluation of miRNA amplification and sequencing for diagnostic potential.
Main Results:
- Maternal plasma miRNA expression levels are correlated with the presence of infant birth defects.
- miRNAs demonstrate potential for early detection of embryonic malformations, surpassing current protein-based biomarkers.
- Further validation is required to establish the reliability and sensitivity of miRNAs as diagnostic markers.
Conclusions:
- Cell-free microRNAs (miRNAs) represent a promising avenue for the early, non-invasive detection of congenital birth defects.
- Amplification and sequencing of miRNAs offer a potentially sensitive and specific method for identifying embryonic developmental abnormalities.
- Future research should focus on validating miRNA biomarkers for widespread clinical application in prenatal diagnostics.
Abstract:
Congenital birth defects, manifested in newborn infants, are formed during early embryogenesis. Targeted and individualized interventions to prevent birth defects require early detection of risk and signs of developmental abnormalities. Current diagnosis of structural anomalies largely relies on ultrasonography, which can only detect abnormities after their formation in fetuses. Biomolecules, mainly proteins, in maternal blood have been used as indicators of fetal anomalies; however, they lack adequate sensitivity for detecting embryonic malformations. Recently, cell-free microRNAs (miRNAs) have been found in blood and evaluated as biomarkers for diseases. Expression of certain miRNAs in maternal plasma has been shown to be correlated with birth defects in infants. Although their reliability and sensitivity remain to be validated, miRNAs, which can be amplified and sequenced, are potentially sensitive and specific biomarkers for early embryonic dysmorphogenesis.
More Related Videos
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
07:27High Throughput MicroRNA Profiling: Optimized Multiplex qRT-PCR at Nanoliter Scale on the Fluidigm Dynamic ArrayTM IFCs
Published on: August 3, 2011
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs